Gentian Diagnostics AS
Company Profile
Business description
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in-vitro diagnostic reagents (IVD) for use in medical diagnostics and research. Its portfolio and pipeline of reagents span areas of inflammations, severe infections, kidney diseases, heart failures, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP among others. Geographically, it generates a majority of its revenue from Europe followed by Asia and the United States of America.
Contact
Bjornasveien 5
Moss1596
NORT: +47 99339905
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
65
Stocks News & Analysis
stocks
Wildly overvalued ASX stock is skating on thin ice
stocks
Uber flexes its network effect and delivers strong result
stocks
Ask the analyst: Are Qantas shares a value trap?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,102.00 | 9.10 | -0.10% |
CAC 40 | 7,649.99 | 14.96 | 0.20% |
DAX 40 | 23,957.65 | 33.29 | 0.14% |
Dow JONES (US) | 44,193.12 | 81.38 | 0.18% |
FTSE 100 | 9,132.62 | 31.69 | -0.35% |
HKSE | 25,058.00 | 147.37 | 0.59% |
NASDAQ | 21,169.42 | 252.87 | 1.21% |
Nikkei 225 | 41,059.15 | 264.29 | 0.65% |
NZX 50 Index | 12,887.10 | 6.94 | 0.05% |
S&P 500 | 6,345.06 | 45.87 | 0.73% |
S&P/ASX 200 | 8,831.40 | 12.30 | -0.14% |
SSE Composite Index | 3,639.67 | 5.67 | 0.16% |